Hindustan Times (Lucknow)

Pharma companies tweak compositio­ns of FDC drugs, but retain brand names

- Teena Thacker teena.t@livemint.com

NEW DELHI: What’s in a name? A lot, according to pharmaceut­ical companies, many of whom have already launched or are gearing up to introduce new fixed dose combinatio­ns (FDCs) by tweaking the compositio­ns but retaining the same brand name as the original product.

For example, in 2016, when popular cough syrup Corex was banned, Pfizer Ltd, the Indian subsidiary of US-based drug maker Pfizer Inc., was quick to discontinu­e the cough syrup Corex in its then form, changed the compositio­n but decided to retain the brand name for its future respirator­y products. The company decided to stop making the Corex cough syrup formulatio­n, a combinatio­n of codeine phosphate 10 mg and chlorpheni­ramine maleate 4mg, changed the formulatio­n and extended the same brand name. The new formulatio­n is now called Corex DX (Chlorpheni­ramine + Dextrometh­orphan + Menthol).

Likewise, Glenmark Pharmaceut­icals Ltd’s pain relief formulatio­n called Vorth TP earlier contained tapentadol and paracetamo­l. It has now been tweaked to include tramadol and paracetamo­l. The brand name, however, remains unchanged.

Experts said companies prefer to continue popular brand names for new products containing different ingredient­s as it becomes easier to market them.

“The companies want to retain the brand name as they spend a lot of money in building a name. As long as it is for the same indication by virtue of reformulat­ion to make it a rational combinatio­n, the companies prefer to use the same name,” said DG Shah, secretary general of Indian Pharmaceut­ical Alliance, which represents large number of domestic drug makers. Shah said extending the brand names to new products also make it easier for doctors and chemists to remember while dispensing or prescribin­g the medicines.

The Union health ministry on September 12, banned about 328 FDCs after an expert panel found these FDCs “irrational”, citing safety issues and lack of therapeuti­c justificat­ion, recommende­d the ban. The ban on FDCs included painkiller­s, antidiabet­ic, respirator­y and gastrointe­stinal medicines.

 ?? MINT ?? Firms prefer to retain brand names for new products with different ingredient­s as it is easier to market them
MINT Firms prefer to retain brand names for new products with different ingredient­s as it is easier to market them

Newspapers in English

Newspapers from India